Stock comparison
Genmab A/S
HUTCHMED (China) Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
HCM
HUTCHMED (China) Limited
Market cap
$2.09B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | HCM | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 15F | GMAB |
| Benjamin Graham | 64C | 35D | GMAB |
| Philip Fisher | 48D | 18F | GMAB |
| Peter Lynch | 25F | 31F | HCM |
| Joel Greenblatt | 76B | 35D | GMAB |
| Charlie Munger | 68C | 14F | GMAB |
| Terry Smith | 71C | 15F | GMAB |
Side-by-side metrics
| Metric | GMAB | HCM |
|---|---|---|
| Market cap | $16.5B | $2.09B |
| P/E (TTM) | 6.2x | 4.8x |
| EV/EBIT | 12.0x | - |
| ROIC (TTM) | 43.78% | -0.69% |
| Gross margin | 93.88% | 18.62% |
| Net margin | 18.23% | 104.77% |
| Revenue CAGR 5y | -18.45% | 11.48% |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs -0.69%+102%
- Market cap$16.5Bvs $2.09B+87%
- Gross margin93.88%vs 18.62%+80%
- Debt / Equity0.1xvs 0.1x+7%
HCM leads on
- Revenue CAGR 5y11.48%vs -18.45%+162%
- EV/EBIT-vs 12.0x+130%
- Net margin104.77%vs 18.23%+83%
- P/E (TTM)4.8xvs 6.2x+22%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.